Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,748 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01219699 | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | completed | Phase 1 | 221 | Novartis PharmaceuticalsINDUSTRY | 5 | Sep 22, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 |
| clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT02079636 | A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | completed | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 11, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 | 50 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | terminated | Phase 1 | 77 | Debiopharm International SAINDUSTRY | 5 | Sep 9, 2020 | clinicaltrials |
| NCT03539484 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | terminated | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 4 | Sep 3, 2020 | clinicaltrials |
| NCT02323191 | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 221 | Hoffmann-La RocheINDUSTRY | 4 | Aug 27, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT02824042 | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | completed | Phase 1 | 63 | BayerINDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | AbbVieINDUSTRY | 5 | Jul 17, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT04029805 | Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels | unknown | Phase 1 / Phase 2 | 34 | Biosearch S.A.INDUSTRY | 1 | Jul 10, 2020 | clinicaltrials |
| NCT02411591 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 66 | Eli Lilly and CompanyINDUSTRY | 3 | Jul 9, 2020 | clinicaltrials |
| NCT02812875 | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas | completed | Phase 1 | 71 | Curis, Inc.INDUSTRY | 4 | Jun 26, 2020 | clinicaltrials |
| NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | completed | Phase 1 / Phase 2 | 267 | Hoffmann-La RocheINDUSTRY | 10 | Jun 11, 2020 | clinicaltrials |
| NCT01742286 | Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) | completed | Phase 1 | 83 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 9, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT01884285 | AZD8186 First Time In Patient Ascending Dose Study | completed | Phase 1 | 147 | AstraZenecaINDUSTRY | 4 | May 29, 2020 | clinicaltrials |
| NCT03674502 | Safety of ADU-1604 in Adults With Metastatic Melanoma | terminated | Phase 1 | 4 | Aduro Biotech, Inc.INDUSTRY | 2 | May 26, 2020 | clinicaltrials |
| NCT03661515 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML(FLAGINEXOR) | completed | Phase 1 | 16 | PETHEMA FoundationOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02261714 | Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 32 | Targovax ASAINDUSTRY | 3 | May 14, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT00983619 | A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies | completed | Phase 1 / Phase 2 | 136 | MedImmune LLCINDUSTRY | 5 | May 13, 2020 | clinicaltrials |
| NCT02013219 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Apr 21, 2020 | clinicaltrials |
| NCT01548924 | Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors | terminated | Phase 1 | 13 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT02324257 | A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors | completed | Phase 1 | 149 | Hoffmann-La RocheINDUSTRY | 7 | Apr 17, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT01058707 | Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies | completed | Phase 1 | 198 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 1, 2020 | clinicaltrials |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 18, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | completed | Phase 1 | 196 | GlaxoSmithKlineINDUSTRY | 7 | Mar 16, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | completed | Phase 1 | 122 | PharmaMarINDUSTRY | 2 | Mar 9, 2020 | clinicaltrials |
| NCT02401542 | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-21) | terminated | Phase 1 / Phase 2 | 71 | Rainier TherapeuticsINDUSTRY | 9 | Mar 9, 2020 | clinicaltrials |
| NCT02261220 | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 380 | MedImmune LLCINDUSTRY | 9 | Mar 6, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT02327169 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | completed | Phase 1 | 81 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | Feb 25, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02496520 | Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults(DEND/TIA) | completed | Phase 1 / Phase 2 | 6 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT04158700 | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 3 | Feb 19, 2020 | clinicaltrials |
| NCT02219724 | A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 174 | Genentech, Inc.INDUSTRY | 6 | Feb 5, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials